Picavet Beheer SPRL
Picavet Beheer reported total assets of 377,326 € at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Mar 2026).
The score of Picavet Beheer shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -87 % Total assets -44 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Picavet Beheer's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −95,594 € | ||||
| Equity | 39,274 € | ||||
| Cash | 5,064 € | ||||
| EBITDA | 22,550 € | ||||
| Total assets | 377,326 € |
Filed annual accounts
- Year ended 31 Aug 2025filed on 26 Mar 2026
- Year ended 31 Aug 2024filed on 07 Mar 2025
- Year ended 31 Aug 2023filed on 27 Dec 2023
- Year ended 31 Aug 2022filed on 09 Mar 2023
- Year ended 31 Aug 2021filed on 24 Feb 2022
Picavet Beheer's financial analysis
- Solvency10.4%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Picavet Beheer
Picavet Beheer's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0447.457.139
- VAT number
- BE0447457139
- Peppol
- Registered · 0208:0447457139 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 22 May 1992
- Registered office
- 2900 Schoten
- Latest accounts
- 2025 · filed on 26 Mar 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 2110001)
Picavet Beheer (SPRL) has been based in Schoten since 1992, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 95,594 € and equity of 39,274 €; its revenue is not published. Its solvency stands at 10.4%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Picavet Beheer
Companies in the same business, of comparable size and area, outside its group.
- Dr. Ilse Mertens, nucleaire geneeskunde Medical specialists activities Pajottegem · balance sheet 377,300 €
- Huisartsen Houtem General medical practice activities Sint-Lievens-Houtem · balance sheet 377,292 €
- Docteur Makhlouf Joseph Medical specialists activities Braine-l'Alleud · balance sheet 377,368 €
- Protector Buying and selling of own real estate Bruges · balance sheet 377,378 €
- Olivier FRANCOIS Dental practice care activities Namur · balance sheet 377,380 €
- Gleeve Manufacture of basic pharmaceutical products Destelbergen · balance sheet 377,263 €
- Foncière de Molenbeek Buying and selling of own real estate Brussels · balance sheet 377,261 €
Frequently asked questions about Picavet Beheer
What is the revenue of Picavet Beheer?
Picavet Beheer files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Picavet Beheer?
In Belgium, the VAT number is the company number prefixed with BE: BE0447457139 for Picavet Beheer, if the company is VAT-registered. Its company number (CBE) is 0447.457.139.
Where is the registered office of Picavet Beheer?
According to the CBE register, the registered office of Picavet Beheer is in 2900 Schoten.
What is the equity of Picavet Beheer?
At the close of the 2025 financial year, the equity of Picavet Beheer amounts to 39,274 €, a solvency of 10.4% of total assets.
Who manages Picavet Beheer?
The register lists 2 active mandates at Picavet Beheer. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Picavet Beheer
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →